Health Care

News Release | U.S. PIRG | Public Health, Health Care

Our Statement on the Failure of the US Senate Health Care Bill

American consumers can breathe a sigh of relief today. The legislation that was narrowly defeated in the US Senate last night threatened to spark chaos in health insurance markets, raise costs, degrade quality of care, weaken protections for people with pre-existing conditions, and cause millions of Americans to lose health coverage.

News Release | Health Care

Our Statement on Senate Health Care Bill

Statement by Jesse Ellis O’Brien, WISPIRG Health Care Advocate, on public release of the “Better Care Reconciliation Act.” 

News Release | Health Care

Great News for Consumers: Anthem Drops Bid to Take Over Cigna

This morning, health insurance giant Anthem dropped its troubled bid to take over one of its top competitors, Cigna. A February district court decision to block the proposed merger on anti-trust grounds was recently upheld by the DC Circuit Court of Appeals, but with Anthem’s decision today, this anti-competitive takeover bid is finally laid to rest. This development comes after months of work by WISPIRG and a broad coalition of consumer and health care groups, urging close scrutiny of the merger from state and federal regulators and raising questions and concerns about the potential impact on consumers.

This week, in a big win for consumers, a district court took action to block the proposed merger between health insurance giants Anthem and Cigna. This decision follows a ruling last month that blocked the proposed merger of two more of the nation’s biggest for-profit health insurers, Aetna and Humana. These decisions come after months of work by U.S. PIRG and a broad coalition of consumer and health care groups, urging close scrutiny of the mergers from state and federal regulators and raising questions and concerns about the potential impact of the mergers.

Report | WISPIRG Foundation | Health Care

Should I Stay or Should I Go?

Many consumers who buy their own health insurance face a big decision right now. Should you renew your existing plan, or switch to a new one?  Here are our tips for consumers, and a checklist to help you make the decision that’s right for you:

Resource | Health Care

SO YOU NEED HEALTH INSURANCE. NOW WHAT?

Having the facts can make all the difference when it comes to health insurance. To make the most of new choices, protections and financial help, you need good information. This guide can help you find quality coverage that won’t break the bank.
 

 

Media Hit | Health Care

Using 'Pay for Delay,' Big Pharma Pockets $98 Billion

What if I told you that major pharmaceutical companies had paid off their competition to delay the release of lower-cost generic drugs for 20 major pharmaceuticals? And that combined, brand name drug companies made an estimated $98 billion in total sales of these 20 drugs while the generic versions were delayed? Unfortunately, it’s true, and it means that too many sick Wisconsinites either can’t afford the prescription medication they need, or are paying 10 times too much.
 

Report | WISPIRG | Health Care

Top 20 Pay for Delay Drugs

Too often, consumers are forced to shoulder a heavy financial burden, or even go without needed medicine, due to the high cost of brand-name drugs. Our research indicates that one significant cause is the practice called “pay for delay,” which inflates the drug prices paid by tens of millions of Americans.
 

News Release | WISPIRG | Health Care

Twenty Top Generic Drugs Delayed By Industry Payoffs

Wisconsinites with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs, according to a report released by the Wisconsin Public Interest Research Group (WISPIRG) and Community Catalyst. The report, “Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers,” reveals that these drugs were subject to an industry practice called “pay for delay,” in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay higher brand-name drug prices.
 

A New Direction In Driving Trends

After a 60 year boom, driving is on the decline in the U.S. and no likely scenario shows it returning to previous levels of growth. 

Pages

Subscribe to RSS - Health Care

Defend the CFPB

Tell your senators to oppose the “Financial CHOICE Act,” which would gut Wall Street reforms and destroy the Consumer Financial Protection Bureau as we know it.

Support Us

Your donation supports WISPIRG's work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code